Similar articles for PMID: 32591490

Year	Number of Results
1996	1
1999	1
2001	1
2004	1
2006	1
2007	2
2008	3
2009	1
2011	5
2012	4
2013	10
2014	9
2015	12
2016	10
2017	12
2018	8
2019	11
2020	21
2021	4

1

¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.

Peterson LM, Kurland BF, Yan F, Jiresova AN, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, Eary JF, Mankoff DA, Linden HM. Peterson LM, et al. J Nucl Med. 2021 Feb;62(2):184-190. doi: 10.2967/jnumed.120.244459. Epub 2020 Jun 26. J Nucl Med. 2021. PMID: 32591490

2

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Kurland BF, et al. Clin Cancer Res. 2017 Jan 15;23(2):407-415. doi: 10.1158/1078-0432.CCR-16-0362. Epub 2016 Jun 24. Clin Cancer Res. 2017. PMID: 27342400 Free PMC article.

3

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Kurland BF, et al. J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8. J Nucl Med. 2011. PMID: 21903739 Free PMC article.

4

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Linden HM, et al. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750198 Free PMC article.

5

Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.

Kumar M, Salem K, Jeffery JJ, Yan Y, Mahajan AM, Fowler AM. Kumar M, et al. J Nucl Med. 2020 Aug 28:jnumed.120.249508. doi: 10.2967/jnumed.120.249508. Online ahead of print. J Nucl Med. 2020. PMID: 32859700

6

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.

Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N. Gemignani ML, et al. J Nucl Med. 2013 Oct;54(10):1697-702. doi: 10.2967/jnumed.112.113373. Epub 2013 Aug 22. J Nucl Med. 2013. PMID: 23970364 Free PMC article. Clinical Trial.

7

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP. Venema CM, et al. J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14. J Nucl Med. 2017. PMID: 28912144 Free article. Clinical Trial.

8

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer ¹⁸F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta H, van Lier JE, Guérin B, Lecomte R, Turcotte ÉE. Paquette M, et al. J Nucl Med. 2018 Feb;59(2):197-203. doi: 10.2967/jnumed.117.194654. Epub 2017 Aug 10. J Nucl Med. 2018. PMID: 28798032 Free PMC article. Clinical Trial.

9

The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.

Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, Wang M, Yuan H, Hu S, Shi W, Zhu B, Zhang Y. Yang Z, et al. Clin Nucl Med. 2017 Jun;42(6):421-427. doi: 10.1097/RLU.0000000000001587. Clin Nucl Med. 2017. PMID: 28221191

10

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

van Kruchten M, Glaudemans AWJM, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GAP. van Kruchten M, et al. Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1674-1681. doi: 10.1007/s00259-015-3107-5. Epub 2015 Jun 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 26091705 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed